RECURRENT LENTIGO MALIGNA: CONSERVATIVE CONTINUOUS TREATMENT WITH IMIQUIMOD OR REPEATED SURGERY? A LONG-TERM FOLLOW-UP DERMOSCOPIC CASE STUDY

Authors

  • V. De Giorgi Section of Dermatology, Department of Health Sciences, University of Florence, Florence50121, Italy
  • B. Zuccaro Section of Dermatology, Department of Health Sciences, University of Florence, Florence50121, Italy
  • F. Silvestri Section of Dermatology, Department of Health Sciences, University of Florence, Florence50121, Italy
  • F. Venturi Section of Dermatology, Department of Health Sciences, University of Florence, Florence50121, Italy
  • J. Colombo Section of Dermatology, Department of Health Sciences, University of Florence, Florence50121, Italy
  • L. Trane Cancer Research “AttiliaPofferi” Foundation, Pistoia 51100, Italy

DOI:

https://doi.org/10.15407/exp-oncology.2023.01.125

Keywords:

dermoscopy, lentigo maligna, melanoma

Abstract

A case of recurrent lentigo maligna in a 45-year-old woman is presented. The disease relapsed several times following the surgical excision of the lesion. An alternative treatment with imiquimod 5% cream was then used. After 4 years of follow-upfrom the last surgery, this treatment achieved total clearance of the lesion. The problems of lentigo maligna diagnosis and treatment are discussed.

References

Bosbous MW, Dzwierzynski WW, Neuburg M. Lentigo maligna: diagnosis and treatment. Clin Plast Surg 2010; 37: 35–46. doi: 10.1016/j.cps.2009.08.006

Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions:

results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48: 679–693. doi: 10.1067/mjd.2003.281

Stante M, Giorgi V, Stanganelli I, et al. Dermoscopy for early detection of facial lentigo maligna. Br J Dermatol 2005; 152: 361–364. doi: 10.1111/j.1365-2133.2004.06328.x

Swetter, SM. Challenges of treating melanoma insitu, lentigo maligna type: is pathological clearance the gold standard? Br J Dermatol 2017; 176: 1115–1116. doi: 10.1111/bjd.15512

Vieira C, Jennings T, Renzi MA Jr, et al. Recurrence rate for melanoma excised by Mohs micrographic surgery without immunostaining. Dermatol Surg 2022; 48: 492–497. doi: 10.1097/DSS.0000000000003435

Franca K, Alqubaisy Y, Hassanein A, et al.Histopathologic pitfalls of Mohs micrographic surgery and a review of tumor histology. Wien Med Wochenschr 2018; 168: 218–227. doi: 10.1007/s10354-016-0528-0

Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol 2002; 46: 78–84. doi: 10.1067/mjd.2002.119197

De Giorgi V, Salvini C, Chiarugi A, et al. In vivo characterization of the inflammatoryinfiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol 2009; 48: 312–321. doi: 10.1111/j.1365-4632.2009.03916.x

Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol 2015; 73: 205–212. doi: 10.1016/j.jaad.2015.05.022

Savarese I, Papi F, D’Errico A, et al. Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells. Clin Exp Dermatol 2015; 40: 27–30. doi: 10.1111/ced.12469

Downloads

Published

26.06.2023

How to Cite

De Giorgi, V., Zuccaro, B., Silvestri, F., Venturi, F., Colombo, J., & Trane, L. (2023). RECURRENT LENTIGO MALIGNA: CONSERVATIVE CONTINUOUS TREATMENT WITH IMIQUIMOD OR REPEATED SURGERY? A LONG-TERM FOLLOW-UP DERMOSCOPIC CASE STUDY. Experimental Oncology, 45(1), 125–129. https://doi.org/10.15407/exp-oncology.2023.01.125

Issue

Vol. 45 No. 1 (2023): Experimental Oncology

Section

Case report

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)